Fig. 01 Outcomes of anti-VEGF treatment stratified by baseline VA. Patients with the best VA at baseline also had the best VA at the 24-month follow-up. While patients with the lowest VA at baseline improved by the most letters, their final VA at the 24-month assessment was still the lowest of all groups. (Image courtesy of Dr Loewenstein)

Fig. 02 Percentage of patients with VA ≥ 20/40 at detection in various AMD studies. In most studies of AMD, a very low percentage of patients have VA ≥ 20/40. This may imply that patients are simply not being diagnosed with AMD at this stage, but only after significant declines in VA. (The HOME Study: ForeseeHome in AREDS2 – Presentation by Dr Susan Bressler AAO 2013). (Image courtesy of Dr Loewenstein)

Fig. 03 Percentage of patients with VA ≥ 20/40 at detection in various AMD studies. In most studies of AMD, a very low percentage of patients have VA ≥ 20/40. This may imply that patients are simply not being diagnosed with AMD at this stage, but only after signifi cant declines in VA. (The HOME Study: ForeseeHome in AREDS2 – Presentation by Dr Susan Bressler AAO 2013). (Image courtesy of Dr Loewenstein)

Fig. 04 Percentage of patients with VA ≥ 20/40 at detection in various AMD studies. In most studies of AMD, a very low percentage of patients have VA ≥ 20/40. This may imply that patients are simply not being diagnosed with AMD at this stage, but only after significant declines in VA. (The HOME Study: ForeseeHome in AREDS2 – Presentation by Dr Susan Bressler AAO 2013). (Image courtesy of Dr Loewenstein)